2014•Journal of Clinical OncologyRequires access

2013 Update of the American Society of Clinical Oncology/College of American Pathologists Guideline for Human Epidermal Growth Factor Receptor 2 Testing: Impact on Immunohistochemistry-Negative Breast Cancers

Kathleen Lambein, Mieke Van Bockstal, Hannelore G Denys, Louis J. Libbrecht

Open publisher page 22 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 22 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Medicine, Human Epidermal Growth Factor Receptor 2, Clinical Oncology, Guideline, Immunohistochemistry, Oncology, Internal medicine, Epidermal growth factor receptor

Back to paper search Browse research topics Original source

2013 Update of the American Society of Clinical Oncology/College of American Pathologists Guideline for Human Epidermal Growth Factor Receptor 2 Testing: Impact on Immunohistochemistry-Negative Breast Cancers — Research Paper | ScholarLens